TABLE 6.
Cytokine levels in blister fluid from lipopeptide-injected subjects (OspC-1 and 17-L) and erythema migrans lesions (EM)a
| Cytokine | Cytokine level in BF
|
|||
|---|---|---|---|---|
| Control blood (n = 6) | OspC-1 (n = 14) | 17-L (n = 7) | EM (n = 20) | |
| IFN-γ | 12.6 (7.8-17.3) | 73.9 (21.4-126.5)b | 55.2 (8.6-101.7)b | 3590.4 (390.8-6790.9)c |
| TNF-α | 1.9 (0.9-2.9) | 11.7 (2.0-21.5) | 3.7 (1.8-5.5) | 31.0 (9.4-52.6) |
| IL-2 | 4.5 (2.9-6.0) | 11.5 (0.1-23.0) | 6.5 (2.7-9.1) | 12.6 (5.4-19.8) |
| IL-4 | 5.7 (2.3-9.1) | 11.4 (2.2-20.7) | 7.1 (3.3-10.9) | 15.1 (10.2-20.1) |
| IL-5 | 6.9 (−2.3-16.2) | 12.2 (−2.8-27.2) | ND | 24.9 (19.8-30.1) |
| IL-6 | 11.7 (−11.8-35.3) | 1448 (34.6-2863.2)b | 2309.1 (412.7-4205.5)b | 3535.9 (1207.8-5864.1)b |
| IL-10 | 2.5 (1.9-3.2) | 47.1 (22.4-71.4)b | 303.4 (−64.4-671.2)b | 84.1 (7.4-169.8)b |
| IL-12 | 21.4 (−8.0-50.9) | 52.3 (0.8-103.9) | 88.5 (49.1-127.9)b | 1495.7 (−7.9-2999.7)d |
a
Numbers shown are mean pictogram values with 95% confidence intervals in parentheses.
b
Significantly different (P < 0.05), lipopeptide-induced BF versus control PB.
c
Significantly different (P < 0.05), lipopeptide-induced BF versus EM.
d
P = 0.058, OspC1 versus EM from Lyme disease patients; and P = 0.06 (17-l versus LD).